These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 15335310

  • 21. Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.
    Brendel C, Hänseler W, Wohlgensinger V, Bianchi M, Tokmak S, Chen-Wichmann L, Kuzmenko E, Cesarovic N, Nicholls F, Reichenbach J, Seger R, Grez M, Siler U.
    Hum Gene Ther Methods; 2013 Jun; 24(3):151-9. PubMed ID: 23489116
    [Abstract] [Full Text] [Related]

  • 22. Gene therapy of chronic granulomatous disease (CGD) by gene transfer into hematopoietic stem cells.
    Zentilin L, Tafuro S, Serra C, Falaschi A, Giacca M.
    Ann Ist Super Sanita; 1998 Jun; 34(4):447-55. PubMed ID: 10234875
    [Abstract] [Full Text] [Related]

  • 23. Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease.
    Mardiney M, Jackson SH, Spratt SK, Li F, Holland SM, Malech HL.
    Blood; 1997 Apr 01; 89(7):2268-75. PubMed ID: 9116268
    [Abstract] [Full Text] [Related]

  • 24. Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects.
    Chiriaco M, Salfa I, Di Matteo G, Rossi P, Finocchi A.
    Pediatr Allergy Immunol; 2016 May 01; 27(3):242-53. PubMed ID: 26680691
    [Abstract] [Full Text] [Related]

  • 25. Lentiviral Gene Therapy of Chronic Granulomatous Disease: Functional Assessment of Universal and Tissue-Specific Promoters.
    Yuan H, Wu X, Liu H, Chang LJ.
    Hum Gene Ther; 2023 Jan 01; 34(1-2):19-29. PubMed ID: 36274229
    [Abstract] [Full Text] [Related]

  • 26. Hematopoietic Tumors in a Mouse Model of X-linked Chronic Granulomatous Disease after Lentiviral Vector-Mediated Gene Therapy.
    Jofra Hernández R, Calabria A, Sanvito F, De Mattia F, Farinelli G, Scala S, Visigalli I, Carriglio N, De Simone M, Vezzoli M, Cecere F, Migliavacca M, Basso-Ricci L, Omrani M, Benedicenti F, Norata R, Rancoita PMV, Di Serio C, Albertini P, Cristofori P, Naldini L, Gentner B, Montini E, Aiuti A, Mortellaro A.
    Mol Ther; 2021 Jan 06; 29(1):86-102. PubMed ID: 33010230
    [Abstract] [Full Text] [Related]

  • 27. Ten years of gene therapy for primary immune deficiencies.
    Aiuti A, Roncarolo MG.
    Hematology Am Soc Hematol Educ Program; 2009 Jan 06; ():682-9. PubMed ID: 20008254
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Gene therapy for chronic granulomatous disease.
    Kang EM, Malech HL.
    Methods Enzymol; 2012 Jan 06; 507():125-54. PubMed ID: 22365772
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Stable long-term gene correction with low-dose radiation conditioning in murine X-linked chronic granulomatous disease.
    Goebel WS, Pech NK, Dinauer MC.
    Blood Cells Mol Dis; 2004 Jan 06; 33(3):365-71. PubMed ID: 15528159
    [Abstract] [Full Text] [Related]

  • 34. Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease.
    Brendel C, Rothe M, Santilli G, Charrier S, Stein S, Kunkel H, Abriss D, Müller-Kuller U, Gaspar B, Modlich U, Galy A, Schambach A, Thrasher AJ, Grez M.
    Hum Gene Ther Clin Dev; 2018 Jun 06; 29(2):69-79. PubMed ID: 29664709
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Gene therapy for inherited diseases using heamatopoietic stem cells--gene therapy for patients with chronic granulomatous disease].
    Nunoi H, Ishibashi F.
    Hum Cell; 1999 Sep 06; 12(3):103-8. PubMed ID: 10695016
    [Abstract] [Full Text] [Related]

  • 37. Monocyte/macrophage-specific NADPH oxidase contributes to antimicrobial host defense in X-CGD.
    Okura Y, Yamada M, Kuribayashi F, Kobayashi I, Ariga T.
    J Clin Immunol; 2015 Feb 06; 35(2):158-67. PubMed ID: 25666294
    [Abstract] [Full Text] [Related]

  • 38. Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.
    Kaufmann KB, Brendel C, Suerth JD, Mueller-Kuller U, Chen-Wichmann L, Schwäble J, Pahujani S, Kunkel H, Schambach A, Baum C, Grez M.
    Mol Ther; 2013 Mar 06; 21(3):648-61. PubMed ID: 23207695
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.